| Literature DB >> 31664997 |
Anca D Farcas1,2, Augustin C Mot3, Cezara Zagrean-Tuza4, Madalina Ticolea5, Bogdan Sevastre6, Muhittin Kulak7, Radu Silaghi-Dumitrescu4, Alina Parvu5.
Abstract
BACKGROUND: Natural extracts with beneficial biological activities are nowadays of high interest, in various treatment or prophylaxis. Hypericum capitatum has been known for its curative effects for centuries and its extracts have become of interest due to their distinct activity among other Hypericaceae members. In this study, further light is aimed to be shed on the secondary-metabolites composition of H. capitatum extracts, using chromatographic techniques and Electron paramagnetic resonance profiles in alkaline medium. Considering that no previous works explored the anti-inflammatory activity of H. capitatum, here, an in vivo study is also designed in order to evaluate this property by assessing the impact of one of H. capitatum extracts in ameliorating turpentine oil-induced inflammation on rats and to quantify their blood antioxidants level.Entities:
Keywords: Anti-inflammatory; Hypericaceae; Hypericum capitatum; Oxidative stress; Rutin
Mesh:
Substances:
Year: 2019 PMID: 31664997 PMCID: PMC6819352 DOI: 10.1186/s12906-019-2680-8
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Numbering of the extracts and yield (w:w) of extraction
| No. | Part of plant (development stage) | material mass (g) | dried extract (g) | yield (%) |
|---|---|---|---|---|
| 1 | Leaf (pre-flowering stage) | 10.13 | 0.88 | 8.6 |
| 2 | Stem (pre-flowering stage) | 8.58 | 0.62 | 7.2 |
| 3 | Leaf (flowering stage) | 8.512 | 0.53 | 6.3 |
| 4 | Stem (flowering stage) | 24.08 | 0.47 | 2.0 |
| 4 | Flower (flowering stage) | 15.73 | 1.37 | 8.7 |
|
| Whole aerial parts – stem, leaf, flower (flowering stage) | 65.22 | 3.34 | 5.1 |
| 7 | Stem (post flowering) | 21.98 | 0.99 | 4.5 |
| 8 | Root (post-flowering stage) | 30.58 | 0.98 | 3.2 |
| 9 | Whole aerial parts – stem, leaf, flower (post flowering stage) | 21.65 | 1.17 | 5.4 |
| 10 | Powdered seeds | 25.64 | 2.13 | 8.3 |
Fig. 1HPTLC analysis results indicating the main secondary metabolites contained by Hypericum capitatum extracts (each lane contains 8 μL of 10 mg/mL). Std1–2 μL and std. 2–10 μL of standards mixture containing rutin (1 – Rf = 0.07), chlorogenic acid (2 – Rf = 0.18), isoquercitrin (3 – Rf = 0.26), hyperoside (4 – Rf = 0.41), hypericin (5 – Rf = 0.67), quercetin (6 – Rf = 0.86) and kaempferol (7 – Rf = 0.89), all at 100 μg/mL. Std3 - standard of rutin solution – 2 μL from 3.5 mg/mL
Fig. 2HPLC profiles of the studied H. capitatum extracts. Standards: 1 – chlorogenic acid, 2 – p-coumaric acid, 3 – caffeic acid, 4 – rutin, 5- isoquercitrin, 6 – quercitrin, 7 – quercetin, 8 – apigenin, 9 – kaempferol, 10 – chrysin, 11 – hyperforin, 11 – hypericin. By far, the highest chromatographic peak is rutin which accounts more than 70% peak area, in all cases. The y axis is rescaled and adapted for clarity
Elution time (in minutes), found concentrations (μg/mg, dried weight) for the tested standards in the studied samples for different parts of the H. capitatum at pre-flowering (PreF), flowering (F) and post-flowering (PostF) stages. The other standards (2, 3, 8, 10, Fig. 2) are all bellow LOD
In vitro antioxidant activity evaluation using three distinct methods and total phenolic content (TPC). Results are expressed in rutin equivalents (RE), trolox equivalents (TE) and gallic acid equivalents (GE) in dried extract
Legend: DPPH DPPH decoloration assay, TEAC Trolox equivalent antioxidant capacity, β-car. Bl. β-carotene bleaching assay, TPC Total phenolic content determination by Folin-Ciocâlteu method. Extract legend described in Materials and Methods
Fig. 3EPR spectra of all ten studied extracts of H. capitatum and four most representative standards
Fig. 4In vivo antioxidant effects of H. capitatum extract on TOS, TBARS, TAC and OSI levels in serum. Data represent mean ± SEM; One-way ANOVA followed by Bonferroni’s Multiple comparison test; * Significant at p < 0.05; **Significant at p < 0.01; ***Significant at p < 0.00 – compared with C group; # Significant at p < 0.05; ## Significant at p < 0.01; Significant at p < 0.00 – compared with I group; [C- Control; I- Inflammation; Dcf- Diclofenac; I + R- Inflammation + Rutin; I + D1 - Inflammation + Dose 1 of H. capitatum extract; I + D2 - Inflammation + Dose 2 of H. capitatum extract; I + D3 - Inflammation + Dose 3 of H. capitatum extract]
Fig. 5In vivo anti-inflammatory effects of H. capitatum extract on NO and 3-NT levels in serum. Data represent mean ± SEM; One-way ANOVA followed by Bonferroni’s Multiple comparison test; * Significant at p < 0.05; **Significant at p < 0.01; ***Significant at p < 0.00 – compared with C group; # Significant at p < 0.05; ## Significant at p < 0.01; Significant at p < 0.00 – compared with I group;[C- Control; I- Inflammation; Dcf- Diclofenac; I + R- Inflammation + Rutin; I + D1 – Inflammation + Dose 1 of H. capitatum extract; I + D2 - Inflammation + Dose 2 of H. capitatum extract; I + D3 - Inflammation + Dose 3 of H. capitatum extract]
Fig. 6Effects of H. capitatum extract on CAT and SOD activities, as well as SH concentration in serum. Data represent mean ± SEM; One-way ANOVA followed by Bonferroni’s Multiple comparison test; * Significant at p < 0.05; **Significant at p < 0.01; ***Significant at p < 0.00 – compared with C group; # Significant at p < 0.05; ## Significant at p < 0.01; Significant at p < 0.00 – compared with I group; [C- Control; I- Inflammation; Dcf- Diclofenac; I + R- Inflammation + Rutin; I + D1 - Inflammation + Dose 1 of H. capitatum extract; I + D2 - Inflammation + Dose 2 of H. capitatum extract; I + D3 – Inflammation + Dose 3 of H. capitatum extract]
Complete blood count of control and experimental animals. Values are expressed as mean ± SEM
| Parameters | Control | I | Diclofenac-I | R-I | D1-I | D2-I | D3-I |
|---|---|---|---|---|---|---|---|
| WBC (10^9/L) | 7.53 ± 0.32 | 10.36 ± 0.58 * | 4.77 ± 0.62#*** | 5.43 ± 0.31#*** | 8.05 ± 0.55 | 6.57 ± 0.29#** | 5.50 ± 0.93#*** |
| LYM (10^9/L) | 6.31 ± 0.79 | 6.46 ± 0.65 | 4.26 ± 0.44 | 4.58 ± 0.42 | 6.39 ± 0.24 | 5.76 ± 0.44 | 4.64 ± 0.23 |
| MON (10^9/L) | 0.61 ± 0.18 | 0.65 ± 0.16 | 0.46 ± 0.18 | 0.28 ± 0.08 | 0.52 ± 0.14 | 0.42 ± 0.09 | 0.38 ± 0.09 |
| NEU (10^9/L) | 1.48 ± 0.07 | 3.03 ± 0.14 ** | 1.04 ± 0.08#*** | 1.63 ± 0.39#* | 2.60 ± 0.59 | 1.96 ± 0.29 | 1.36 ± 0.13#** |
| RBC(10^12/L) | 8.40 ± 0.37 | 9.11 ± 0.34 | 8.59 ± 0.16 | 8.66 ± 0.15 | 8.88 ± 0.17 | 8.61 ± 0.06 | 9.24 ± 0.14 |
| HGB (g/dL) | 14.20 ± 0.55 | 14.85 ± 0.36 | 14.64 ± 0.27 | 15.08 ± 0.27 | 14.88 ± 0.19 | 14.88 ± 0.36 | 15.26 ± 0.21 |
| HCT(%) | 43.78 ± 1.48 | 46.02 ± 1.57 | 44.98 ± 0.67 | 45.69 ± 1.09 | 45.74 ± 0.78 | 46.50 ± 0.92 | 46.67 ± 0.71 |
| MCV(fl) | 52.20 ± 1.39 | 49.20 ± 0.73 | 52.20 ± 0.58 | 52.60 ± 1.40 | 51.60 ± 0.74 | 52.00 ± 1.04 | 50.40 ± 0.87 |
| MCH(pg) | 16.92 ± 0.34 | 16.24 ± 0.28 | 17.06 ± 0.32 | 17.40 ± 0.32 | 16.74 ± 0.12 | 16.90 ± 0.46 | 16.52 ± 0.12 |
| MCHC(g/dL) | 32.44 ± 0.29 | 32.92 ± 0.35 | 32.56 ± 0.36 | 32.98 ± 0.28 | 32.56 ± 0.43 | 32.56 ± 0.61 | 32.72 ± 0.36 |
| RDWs(%) | 17.04 ± 0.21 | 17.20 ± 0.27 | 17.04 ± 0.11 | 16.62 ± 0.20 | 17.00 ± 0.20 | 17.18 ± 0.28 | 17.24 ± 0.39 |
| PLT(10^9/L) | 737.8 ± 190.8 | 944 ± 94.61 | 800.4 ± 61.83 | 840 ± 50.71 | 902.4 ± 65.56 | 840.2 ± 25 | 784.4 ± 67.7 |
| PCT(%) | 0.51 ± 0.13 | 0.65 ± 0.05 | 0.54 ± 0.03 | 0.57 ± 0.03 | 0.62 ± 0.04 | 0.57 ± 0.02 | 0.53 ± 0.06 |
| MPV(fl) | 6.92 ± 0.09 | 6.98 ± 0.15 | 6.80 ± 0.20 | 6.88 ± 0.20 | 6.90 ± 0.04 | 6.88 ± 0.13 | 6.78 ± 0.15 |
| PDWs(%) | 33.54 ± 0.49 | 32.78 ± 0.33 | 32.08 ± 0.23 | 33.08 ± 0.32 | 33.24 ± 0.20 | 32.76 ± 0.46 | 32.58 ± 0.42 |
[WBC White blood cell count, NEU the Number of neutrophils, MON Monocytes, LYM Lymphocytes, RBC Red blood cells count, HGB Haemoglobin concentration, HCT Haematocrit, MCH Mean corpuscular haemoglobin, MCV Mean corpuscular volume, MCHC Mean corpuscular haemoglobin concentration, RDW Red blood cell distribution width, PLT Platelet count, PCT Thrombocytocrit, MPV Medium platelet volume and PDW Platelet distribution width]
* Significant at p < 0.05; ** Significant at p < 0.01; *** Significant at p < 0.001– compared with C group; # Significant at p < 0.05; ## Significant at p < 0.01; Significant at p < 0.001 – compared with I group
Plasma proteins and C reactive protein (CRP) of control and experimental animals. Values are expressed as mean ± SEM
| Parameters | Control | I | Diclofenac-I | R-I | D1-I | D2-I | D3-I |
|---|---|---|---|---|---|---|---|
| TP(g/dL) | 7.60 ± 0.97 | 10.42 ± 0.54a* | 9.87 ± 0.66 | 10.14 ± 0.31 | 9.46 ± 0.26 | 8.80 ± 0.38 | 9.55 ± 0.60 |
| ALB (g/dL) | 2.11 ± 0.22 | 2.8 ± 0.86 | 2.60 ± 0.80 | 2.53 ± 0.85 | 2.75 ± 0.56 | 2.75 ± 0.59 | 2.59 ± 0.7 |
| GLOB (g/dL) | 5.19 ± 0.42 | 7.62 ± 0.54 a* | 7.11 ± 0.32 | 7.05 ± 0.42 | 6.61 ± 0.24 | 6.05 ± 0.32 | 6.86 ± 0.20 |
| CRP (mg/L) | 39.20 ± 2.47 | 73.25 ± 19.19 a* | 42.0 ± 6.38 | 37.0 ± 13.81 | 38.40 ± 8.17 | 21.40 ± 8.17#* | 23.80 ± 6.05#* |
[TP Total proteins, ALB Albumin, GLOB Globulins, CRP C reactive proteins]
* Significant at p < 0.05; ** Significant at p < 0.01; *** Significant at p < 0.001– compared with C group; # Significant at p < 0.05; ## Significant at p < 0.01; Significant at p < 0.001 – compared with I group
a compared with Control